Company news

Zhejiang Medicine Co., Ltd. news in 2026

Zhejiang Medicine Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(600216)"Zhejiang Medicine Co., Ltd."Announcement on Progress in Repurchasing Shares

November 3, 2026

(600216)"Zhejiang Medicine Co., Ltd."Report for Q3 2026

October 27, 2026

(600216)"Zhejiang Medicine Co., Ltd."Announcement on Progress in Repurchasing Shares

October 15, 2026

(600216)"Zhejiang Medicine Co., Ltd."Announcement on Progress in Repurchasing Shares

October 9, 2026

Announcement on Convening the 2026 Semi-annual Performance Briefing

September 7, 2026

Announcement on Progress in Repurchasing Shares

September 1, 2026

Announcement on Resolutions of the 14th Meeting of the 10th Board of Directors

August 25, 2026

Announcement on Initial Repurchase of Shares through Call Auction

August 24, 2026

Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase

July 17, 2026

Announcement on Resolutions of the 13th Meeting of the 10th Board of Directors

July 14, 2026

Announcement on Expiration of the Share Reduction Plan of a Shareholder Holding More Than 5% of the Company's Shares and No Share Reduction

July 7, 2026

Announcement on Implementation of Dividend Distribution for 2025

July 2, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

June 11, 2026

Announcement on Convening Performance Briefing for 2025 and Q1 2026

June 8, 2026

Announcement on Progress in Cooperation in Investment with a Private Fund

May 27, 2026

Announcement on Cooperative Investment with Private Fund

May 15, 2026

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

April 27, 2026

Announcement on the Self-Inspection Report on the Trading of Stocks by Insiders of Inside Information Related to the Spin-off of Affiliated Subsidiaries

April 24, 2026

Announcement on Resolutions of the 12th Meeting of the 10th Board of Directors

April 23, 2026

Announcement on 2025 Annual Profit Distribution Plan

April 10, 2026

Announcement on Plan of Shareholding Reduction through Call Auction by Shareholder with Over 5% Shares

March 16, 2026

Announcement on Initiation of Phase II Clinical Trial of ARX305

March 5, 2026

Announcement on C-Round Capital Increase of Subsidiary Novocodex Biopharmaceuticals with the Introduction of Strategic Investors and Waiver of Preemptive Subscription Rights

March 3, 2026

Announcement on No Shareholding Reduction upon Expiration of Shareholding Reduction Plan by Shareholder with Over 5% Shares

January 22, 2026

Announcement on the Results of Grants for the 2025 Restricted Stock Incentive Plan

January 6, 2026